Literature DB >> 25491934

Tachycardia pacing induces myocardial neovascularization and mobilizes circulating endothelial progenitor cells partly via SDF-1 pathway in canines.

Jingting Mai1,2, Fei Wang3, Qiong Qiu1,2, Buzhou Tang4, YongQing Lin1,2, NianSang Luo1,2, WoLiang Yuan1,2, XiaoLong Wang4, Qingcai Chen4, JingFeng Wang5,6, YangXin Chen7,8.   

Abstract

Neovascularization plays pivotal role in ischemic heart failure; however, it is unclear in non-ischemic heart failure. Non-ischemic heart failure was induced by chronic rapid right ventricular pacing at 200 beats/min, respectively, for 3 and 6 weeks in 12 dogs. Sham-operation was performed in another 6 dogs as control. Three-week tachycardia pacing could induce mild/moderate heart failure and 6-week pacing could induce severe heart failure. Pan-microvessel density (MVD) was assessed by CD31 and neovascularization density was assessed by CD105. Mean CD31-MVD and CD105-MVD were significantly increased after 3-week pacing. However, CD105-MVD was significantly decreased by 80 % in 6-week pacing group compared with 3-week pacing group, whereas CD31-MVD was only decreased slightly (15 %; P < 0.05). Myocardial proangiogenic factor stromal cell-derived factor 1 (SDF-1), hypoxia-inducible factors 1α (HIF-1α, a transcription factor which could regulate SDF-1 expression), serum SDF-1 levels and circulating EPC mobilization were greatly elevated after 3-week pacing but nearly returned to baseline level after 6-week pacing, which were in accordance with the changes of neovascularization levels assessed by CD105. Angiogenesis and migrating ability of EPCs were enhanced after stimulation of SDF-1, which could be abolished by pretreatment with SDF-1 receptor antagonist AMD3100. In addition, angiogenesis and migrating functions of EPCs were significantly enhanced by the serum from 3-week pacing dogs, but had much weaker response to the serum from 6-week pacing dogs. In conclusion, tachycardia pacing-induced non-ischemic heart failure, promoted myocardial neovascularization and mobilized circulating EPCs, which might be mediated partly through SDF-1 pathway.

Entities:  

Keywords:  Endothelial progenitor cells; Neovascularization; Non-ischemic heart failure; Tachycardia pacing

Mesh:

Substances:

Year:  2014        PMID: 25491934     DOI: 10.1007/s00380-014-0613-5

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  33 in total

1.  Regulation of circulating progenitor cells in left ventricular dysfunction.

Authors:  Barry A Boilson; Katarina Larsen; Adriana Harbuzariu; Sinny Delacroix; Josef Korinek; Harald Froehlich; Kent R Bailey; Christopher G Scott; Brian P Shapiro; Guido Boerrigter; Horng H Chen; Margaret M Redfield; John C Burnett; Robert D Simari
Journal:  Circ Heart Fail       Date:  2010-06-23       Impact factor: 8.790

2.  Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure.

Authors:  Kou-Gi Shyu; Ming-Jen Lu; Hang Chang; Hsien-Yi Sun; Bao-Wei Wang; Peiliang Kuan
Journal:  J Card Fail       Date:  2005-03       Impact factor: 5.712

3.  Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol.

Authors:  L Rössig; J Haendeler; Z Mallat; B Hugel; J M Freyssinet; A Tedgui; S Dimmeler; A M Zeiher
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

4.  Circulating endothelial progenitor cells in congestive heart failure.

Authors:  Mutsuko Nonaka-Sarukawa; Keiji Yamamoto; Hirotaka Aoki; Yoshioki Nishimura; Hidenori Tomizawa; Masaru Ichida; Takayuki Eizawa; Kazuo Muroi; Uichi Ikeda; Kazuyuki Shimada
Journal:  Int J Cardiol       Date:  2006-10-27       Impact factor: 4.164

Review 5.  Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses.

Authors:  Rosalba Salcedo; Joost J Oppenheim
Journal:  Microcirculation       Date:  2003-06       Impact factor: 2.628

Review 6.  CD105 is important for angiogenesis: evidence and potential applications.

Authors:  Sarah E Duff; Chenggang Li; John M Garland; Shant Kumar
Journal:  FASEB J       Date:  2003-06       Impact factor: 5.191

7.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.

Authors:  Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

8.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.

Authors:  Elisabeth M Zeisberg; Oleg Tarnavski; Michael Zeisberg; Adam L Dorfman; Julie R McMullen; Erika Gustafsson; Anil Chandraker; Xueli Yuan; William T Pu; Anita B Roberts; Eric G Neilson; Mohamed H Sayegh; Seigo Izumo; Raghu Kalluri
Journal:  Nat Med       Date:  2007-07-29       Impact factor: 53.440

Review 9.  Animal models of human cardiovascular disease, heart failure and hypertrophy.

Authors:  G Hasenfuss
Journal:  Cardiovasc Res       Date:  1998-07       Impact factor: 10.787

10.  Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.

Authors:  T C Mineo; V Ambrogi; A Baldi; C Rabitti; P Bollero; B Vincenzi; G Tonini
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

View more
  2 in total

1.  A longer total duration of rapid ventricular pacing does not increase the risk of postprocedural myocardial injury in patients who undergo transcatheter aortic valve implantation.

Authors:  Kenta Okitsu; Takeshi Iritakenishi; Tatsuyuki Imada; Mitsuo Iwasaki; Sho Carl Shibata; Yuji Fujino
Journal:  Heart Vessels       Date:  2017-03-20       Impact factor: 2.037

2.  The impact of cardiomotor rehabilitation on endothelial function in elderly patients with chronic heart failure.

Authors:  Juming Chen; Shenhong Gu; Yanling Song; Xinbo Ji; Wangyuan Zeng; Xiaoxi Wang; Yachun Wang; Qingfeng Feng
Journal:  BMC Cardiovasc Disord       Date:  2021-11-01       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.